Evelien Moorkens

8PUBLICATIONS
7CO-AUTHORS
Early English languagesGene expression (incl. microarray and other genome-wide approaches)Other biomedical and clinical sciences not elsewhere classifiedMedical molecular engineering of nucleic acids and proteinsBioinformatic methods development
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Dec 11, 2020
A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study.

Evelien Moorkens, Arnold G Vulto, James Kent

|Oct 24, 2020
Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany.

Evelien Moorkens, Teresa Barcina Lacosta, Arnold G Vulto

|May 14, 2020
Biosimilars in Belgium: a proposal for a more competitive market.

Evelien Moorkens, Arnold G Vulto, Isabelle Huys

|Apr 21, 2020
An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?

Evelien Moorkens, Arnold G Vulto, Isabelle Huys

|Apr 15, 2020
Economic evaluation of biosimilars for reimbursement purposes - what, when, how?

Evelien Moorkens, Hannah Broux, Isabelle Huys

|Apr 05, 2019
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting.

Evelien Moorkens, Steven Simoens, Per Troein

Pageof 2

Frequent Collaborators

4 joint publications

Arnold G Vulto

3 joint publications

Steven Simoens

3 joint publications

Isabelle Huys

1 joint publications

Teresa Barcina Lacosta